A number of research firms have changed their ratings and price targets for Arrowhead Pharmaceuticals (NASDAQ: ARWR):
- 10/15/2026 – Arrowhead Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $109.00 price target on the stock.
- 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $115.00 price target on the stock.
- 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
- 10/14/2026 – Arrowhead Pharmaceuticals was upgraded by UBS Group to “strong-buy”.
- 9/24/2026 – Arrowhead Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “neutral” rating and a $74.00 price target on the stock.
- 9/8/2026 – Arrowhead Pharmaceuticals is now covered by Citigroup. They set a “buy” rating and a $108.00 price target on the stock.
Arrowhead Pharmaceuticals Stock Performance
Shares of NASDAQ:ARWR traded down $0.04 during trading on Tuesday, hitting $59.53. 1,327,133 shares of the company were exchanged, compared to its average volume of 2,235,733. The company has a market cap of $8.39 billion, a PE ratio of -26.46 and a beta of 1.34. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The stock has a 50 day moving average of $69.24 and a 200 day moving average of $71.60. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $37.06 and a 52-week high of $95.49.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The firm’s revenue was up 171.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.26) EPS. As a group, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.62 EPS for the current year.
Insider Activity at Arrowhead Pharmaceuticals
In other news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is owned by corporate insiders.
Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.
Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.
See Also
- Five stocks we like better than Arrowhead Pharmaceuticals
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
